Is Emcure Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers
- September 15, 2026
- Posted by: Harsh Piplani
- Category: Market
Emcure Pharmaceuticals CMP Rs 2,004 (15 Sep 2026). Market cap Rs 37,499 Cr. ROE 18.67%. P/E 36.80x versus Industry P/E 37.96x.
Quick Answer
Emcure Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 18.67% return on equity and a P/E of 36.80x against an Industry P/E of 37.96x. Emcure Pharmaceuticals Ltd develops and manufactures formulations across therapeutic areas including gynaecology, HIV and cardiology, with a presence in India and over 70 export markets. Whether Emcure Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Emcure Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 2,004 as of 15 September 2026, within its 52-week range of Rs 1,260.00 to Rs 2,048.00. Emcure Pharmaceuticals Ltd develops and manufactures formulations across therapeutic areas including gynaecology, HIV and cardiology, with a presence in India and over 70 export markets.
Emcure Pharmaceuticals sits in the Healthcare sector, and its 18.67% ROE and 36.80x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Ltd develops and manufactures formulations across therapeutic areas including gynaecology, HIV and cardiology, with a presence in India and over 70 export markets. At a market capitalisation of Rs 37,499 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Emcure Pharmaceuticals the Best Stock in Its Sector?
Emcure Pharmaceuticals makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 18.67% ROE with a 36.80x P/E against the sector’s 37.96x Industry P/E. Emcure Pharmaceuticals trades almost exactly at its 37.96x Industry P/E, with an 18.67% ROE that compares reasonably against the larger MNC pharma peers used elsewhere in this series.
| Metric | Emcure Pharmaceuticals |
|---|---|
| CMP (NSE) | Rs 2,004.50 |
| 52-Week High / Low | Rs 2,048.00 / Rs 1,260.00 |
| Market Cap | Rs 37,499 Cr |
| P/E (TTM) vs Industry P/E | 36.80x vs 37.96x |
| P/B | 7.58 |
| ROE | 18.67% |
| EPS (TTM) | Rs 53.71 |
| Dividend Yield | 0.18% |
| Debt to Equity | 0.31 |
Compare Emcure Pharmaceuticals Against Other Healthcare Sector Stocks
How Emcure Pharmaceuticals Compares Against Its Healthcare Sector Peers
The table below sets Emcure Pharmaceuticals against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Emcure Pharmaceuticals | 37,499 | 36.80 | 18.67% | 0.31 |
| Pfizer | 18,583 | 25.28 | 17.19% | 0.02 |
| Sanofi India | 7,093 | 21.91 | 39.20% | 0.02 |
| GlaxoSmithKline Pharmaceuticals | 48,064 | 45.00 | 45.69% | 0.01 |
| Peer average (3 companies) | – | 30.73 | 34.03% | 0.02 |
Against this peer set, Emcure Pharmaceuticals’s 18.67% ROE is below the 34.03% peer average, and its P/E of 36.80x runs above the peer average of 30.73x. Emcure Pharmaceuticals trades almost exactly at its 37.96x Industry P/E, with an 18.67% ROE that compares reasonably against the larger MNC pharma peers used elsewhere in this series.
What Makes Emcure Pharmaceuticals Worth Watching in Healthcare
- Close to Industry P/E: A 36.80x P/E versus a 37.96x Industry P/E shows Emcure trading almost exactly at Healthcare sector norms.
- Solid ROE: An 18.67% ROE is a healthy figure for a diversified formulations manufacturer.
- Broad export footprint: A presence across more than 70 export markets diversifies Emcure’s revenue base beyond India alone.
Emcure Pharmaceuticals Valuation: Is It Justified?
Emcure Pharmaceuticals trades almost exactly at its 37.96x Industry P/E, with an 18.67% ROE that compares reasonably against the larger MNC pharma peers used elsewhere in this series. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals and other Healthcare sector stocks.
How to Track Emcure Pharmaceuticals Before You Invest
Before deciding whether Emcure Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Emcure Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Emcure Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 18.67% ROE and a P/E of 36.80x against a 37.96x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Emcure Pharmaceuticals the best stock in its sector?
Ans. Emcure Pharmaceuticals has a 18.67% ROE and trades at 36.80x P/E against a 37.96x Industry P/E, and compares below the peer average ROE of 34.03% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Emcure Pharmaceuticals?
Ans. Emcure Pharmaceuticals was trading at Rs 2,004.50 on the NSE as of 15 September 2026, within its 52-week range of Rs 1,260.00 to Rs 2,048.00.
What sector does Emcure Pharmaceuticals belong to?
Ans. Emcure Pharmaceuticals is classified under the Healthcare sector on Univest.
How does Emcure Pharmaceuticals compare to its sector peers on P/E?
Ans. Emcure Pharmaceuticals’s P/E of 36.80x is above the 30.73x average of the 3 named peers compared in this article.
What is Emcure Pharmaceuticals’s return on equity?
Ans. Emcure Pharmaceuticals reported a return on equity of 18.67%, which is below the 34.03% average of its named peers in this comparison.
Should I invest in Emcure Pharmaceuticals based on its sector position?
Ans. Emcure Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
